本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, June 9, 2026 /PRNewswire/ -- Today, OpenWay, a global provider of digital payment software, announces its collaboration with Visa, a global leader in digital payments, to help financial institutions in Asia Pacific bring new payment propositions to market more efficiently. Banks across Asia Pacific are under increasing pressure to launch new payment experiences more quickly while managing integration complexity, operational resilience, and evolving customer expectations. OpenWay sees growing demand from banks and fintechs for flexible platforms that support faster innovation without large-scale infrastructure replacement. The collaboration enables banks, processors, and fintechs to launch selected Visa payment capabilities faster on OpenWay's Way4 digital software payments platform. Earlier coordination between Visa and OpenWay on selected product requirements and implementation frameworks helps simplify implementation and shorten deployment timelines. By teaming up with Visa, OpenWay gains earlier alignment on selected Visa product requirements and implementation frameworks, helping accelerate readiness for future deployments across Asia Pacific and beyond. Way4 platform supports card issuing, digital wallets, merchant acquiring, real-time payments, and other payment services on a single real-time platform used by banks, processors, and fintechs globally. The platform is designed to help financial institutions launch and scale new payment propositions with high configurability and operational reliability at speed. Way4 can run on premises, in the cloud, as dedicated SaaS, or in hybrid deployment models. This builds on several recent product initiatives supported on Way4. These include Visa Flexible Credential, which allows cardholders to access multiple funding sources through one credential, and Visa Fleet 2.0, which supports fleet-related payment use cases. Additional Visa products and services are expected to follow within the same collaboration framework. "Asia Pacific continues to lead global payment innovation, and banks are looking for ways to deliver new customer propositions faster and more efficiently," said Rudy Gunawan, Managing Director of OpenWay Asia. "Our collaboration with Visa strengthens our ability to support financial institutions with faster implementation of new payment capabilities on Way4." About OpenWay OpenWay is the best-in-class provider of digital payment software solutions for card issuing, digital wallets, merchant acquiring, BNPL, transaction switching, tokenization, and fleet payments, and the best cloud payment systems provider as rated by Gartner, Datos Insights, Ovum, Juniper Research, PayTech. Distinguished as a real-time modern payments software platform, flexible and resilient at scale.
SHANGHAI, June 9, 2026 /PRNewswire/ -- At the opening of the 19th SNEC PV Power Expo, MUST formally unveiled its next-generation PH1100 hybrid solar inverter series and LP3000 modular battery platform, marking a significant expansion of its all-scenario energy storage architecture. The launch drew immediate attention from international distributors, EPC contractors, and project developers converging on the company's booth. All-Scenario Hybrid Energy Storage Solution The newly released PH1100 series delivers a comprehensive power spectrum spanning 3–10 kW single-phase, 5–12 kW split-phase (120V/240V), and 5–25 kW three-phase (380VAC) configurations. Each unit is sealed to IP66 standards with integrated WiFi monitoring, engineered to operate reliably across -25°C to +60°C ambient conditions. Dual MPPT architecture achieves peak efficiency up to 97.8%, while universal battery compatibility accommodates both lithium and lead-acid chemistries. The PH1100-EU series delivers up to 25 kW per unit, with 210 A charge/discharge capability and parallel deployment of up to 16 units, aggregating to 400 kW for microgrid and light-commercial installations. Paired with the PH1100 launch, the LP3000 low-voltage battery system introduces a stackable, field-expandable architecture ranging from 5.12 kWh to 40.96 kWh. Rated IP65 with WiFi connectivity, the LP3000 enables seamless integration with the PH1100 series, allowing users to right-size storage capacity with plug-and-play simplicity. The debut of this hybrid platform anchored MUST's broader SNEC showcase, which spanned its full product ecosystem. The HBP1800 portable solar generators (500W–2kW, 960Wh–5.12kWh) and HBP1900 VPM / HBP1800 ES integrated ESS systems (3.5kW–5.5kW, 3kWh–15.36kWh) address residential energy independence with 6,000+ cycle lifespans. For commercial and industrial sectors, the PH11-60KL3-EU-HV high-voltage inverters (30kW–60kW) and HV2800 ESS batteries (64kWh–240kWh) deliver scalable grid-tied solutions, while the ESG industrial storage system (61.4kWh per cabinet, expandable to 600kWh+) enables peak shaving and emergency backup with integrated fire-suppression safety. Off-grid markets are served by the PV1900 series (4kW–12kW) and LP1600 batteries (2.56kWh–30.72kWh), providing rugged standalone power for remote and mobile applications. MUST's SNEC 2026 launch reaffirms its strategic commitment to building resilient, intelligent, and universally deployable clean energy infrastructure that empowers true energy independence across every climate and continent. About MUST MUST is a global leader in PV inverters and energy storage, with 800,000+ units shipped to 800,000+ households worldwide. It leverages leading R&D and scale to deliver clean energy solutions across all scenarios. For more information, please visit: www.mustpower.com | www.mustenergy.com Email: sns@mustenergy.com
SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement. This collaboration strengthens the Company's cardiovascular portfolio and highlights Everest's continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies. Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe. The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market. "This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest's cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel's development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients." "As our self-developed novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel's global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large." Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023. Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area. As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD. About Sumecigrel Sumecigrel is the world's first new-generation P2Y12 receptor antagonist designed to resolve clopidogrel's heavy reliance on CYP2C19 genetic polymorphism by optimizing its metabolic pathway while retaining clopidogrel's active metabolite. It is indicated for atherothrombotic events including acute coronary syndrome, ischemic stroke and peripheral arterial disease. It stands as one of Vcare PharmaTech's flagship achievements underpinned by the philosophy of differentiated original design to tackle unmet clinical needs. Its molecular design findings were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, which recognized it as one of the most commercially promising projects in the field of novel drugs. Currently in preparation for NDA submissions in multiple countries, Sumecigrel possesses strong Best-in-Class potential and broad commercial prospects, and is expected to reshape the antithrombotic market where no new innovative drugs targeting the same mechanism have been launched for over a decade. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. About Vcare PharmaTech Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Vcare PharmaTech is a commercial-stage innovative biopharmaceutical enterprise adopting AI-enabled differentiated original drug design and dedicated to developing innovative drugs and leading therapies. The Company has built a full-spectrum innovation system covering the entire R&D and industrialization lifecycle of new drugs, from AI-powered differentiated project initiation and preclinical candidate discovery to integrated pharmaceutical development and green manufacturing. It houses the Nanjing Key Laboratory for AI-Driven Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry. Focused on addressing unmet clinical demands via differentiated approaches, Vcare PharmaTech develops a tiered, high-quality and diversified pipeline of innovative drugs targeting treatment resistance, drug resistance and targeted selectivity optimization. Its product portfolio covers major chronic disease areas including inflammation and autoimmunity, cardio-cerebrovascular diseases and oncology, striving to deliver superior treatment solutions for patients worldwide. For more information, please visit www.vcarepharmatech.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Hong Kong's Prime 63 Metro Stations Network Launches Data-Driven "25 Personas" Audience Targeting Solutions HONG KONG, June 9, 2026 /PRNewswire/ -- MTR* advertising, as the market leader, offers the city's broadest media coverage and daily touchpoints leveraging its massive network across 8 metro lines, 63 stations, and 15 interchange stations. Today, it announces a market-disrupting strategic layout – evolving the advantage of "mass coverage" into the revolutionary power of "precision marketing" with the official launch of the "25 Personas" audience targeting solution, providing brands with more precise and higher-converting marketing strategies. MTR* advertising is now rolling out 25 audience-targeted media packages, each mapped to specific audience attributes further strengthening brands' competitive edge in the market. Disruptive Strategy: The Revolution from "Mass Network" to "Precision Marketing"MTR serves over 5.55 million passenger trips daily#, with every commuter following a unique route and destination. To maximize advertising effectiveness and minimize wastage, we break through the traditional media coverage framework to introduce 25 audience targeting segments and solutions. This marks a new market revolution – MTR* advertising not only reaches all citizens across Hong Kong but also empowers brands with "precision marketing" capabilities, making every exposure strategically valuable. Ms. Shirley Chan, Managing Director of JCDecaux Transport Hong Kong and Macau, stated: "In this AI and data-driven marketing era, we are leading OOH advertising to create a brand-new landscape. We provide data-proven main and digital media packages that deliver high precision and high conversion rates, enabling brand promotions to maximize promotional efficiency within the MTR* advertising network and precisely reach their target audiences." Data-Driven Precision Targeting: 25 "Ready-to-Use" Packages Achieve "Simple, Efficient, and Reliable" Placement Combined with the latest NielsenIQ 2024 MTR audience insight data, the marketing model of MTR* advertising has evolved into an audience-targeted strategy. The platform provides 25 ready-to-buy media packages, allowing brands to engage in direct and resonant advertising dialogues with target audiences in the most data-scientific and efficient way, precisely reaching diverse groups. By optimizing MTR* advertising media allocation through data analysis, we ensure that ad messages appear at the stations and locations most frequented by target audiences, helping clients maximize budget efficiency. All-Round Matrix: Integration of Traditional and Digital Media Creates Maximum Sensory ImpactTo ensure brand messages are both precise and impactful, the 25 targeting packages fully integrate the traditional and digital media ecosystem. Utilizing static media to build strong brand memory, combined with digital screens playing dynamic content to boost attractiveness, the visual complementarity effect is significantly enhanced. This summer, the "MTR 25 Personas Challenge" interactive experience will also be launched to deeply drive audience engagement and brand stickiness. Outlook for 2026 OOH Market Revolution: The New Landscape of MTR* advertising Precision MarketingWith the widest geographical coverage and the densest daily touchpoints, we officially open a new era of precision targeting. This transformation, blending data and creativity, will bring unprecedented return on investment (ROI) and market impact to brands. Act fast to secure your spot, please contact our sales team to get more details and placement solutions now! * MTR advertising refers to the advertising exclusively operated by JCDecaux Transport, including the MTR Island Line, South Island Line, Tsuen Wan Line, Kwun Tong Line, Tung Chung Line, Tseung Kwan O Line, Disneyland Resort Line, and Airport Express. # Source: Transport Department, Government of the HKSAR. Passenger trips refer to the number of average daily passenger journeys across MTR Kwun Tong Line, Tsuen Wan Line, Island Line, Tung Chung Line, Disneyland Resort Line, Tseung Kwan O Line, East Rail Line, South Island Line, Tuen Ma Line, High Speed Rail, Airport Express, Light Rail, and MTR Bus. MTR* & Airport Express Advertising Enquiries: Hotline: (852) 2111 0111 Email: info@jcdecaux.com.hkWhatsApp: (852) 9793 2220 https://www.jcdecaux-transport.com.hk/https://www.facebook.com/mtradvertising/https://www.instagram.com/mtradvertisinghk/https://www.youtube.com/@JCDecauxTransportHK
The leading AI-first engineering platform for physical product development, trusted by the world's top OEMs and industrial manufacturers Deepening direct collaboration with Hanwha Ocean and other leading global automotive OEMs and Tier 1 suppliers in the region. Dr. Eunjoo Lee, former CEO of IBM Korea and Executive VP at Samsung, joins as Board Advisor SEOUL, South Korea, June 9, 2026 /PRNewswire/ -- Neural Concept, the world leader in AI-driven physical product development, today announced the opening of its first direct office in Seoul and its first in APAC. The new office reflects growing demand from Korean manufacturers that are moving beyond isolated AI pilots and toward production-scale deployment across engineering teams. Neural Concept has confirmed plans to expand its work, with direct local support now available for deployment, capability-building and long-term engineering transformation. Seoul office leadership team, left to right: Laurent D'Alvise (VP Commercial, APAC), Eunjoo Lee (Board Advisor) and Jiwon Jung (Regional Sales Director) Across Korea's industrial base, engineering teams are under pressure to shorten development cycles while managing rising product complexity. In many organizations, critical workflows still remain fragmented across CAD, simulation and internal data environments, slowing iteration and limiting the impact of AI. "South Korea is one of the world's most advanced manufacturing countries, and it is becoming a defining market for the next generation of engineering, " said Pierre Baqué, CEO and founder at Neural Concept. "The shift is no longer about experimenting with AI around the edges. It is about embedding Engineering Intelligence into core product development workflows. Opening our Seoul office allows us to support that transition directly, with the proximity and long-term commitment our customers expect." "We see Seoul as a strategic base for one of the world's most important engineering ecosystems," said Jiwon Jung, Regional Sales Director for APAC at Neural Concept. "From automotive and electrification to shipbuilding, electronics and semiconductors, Korean manufacturers are setting the pace in industrial innovation. A direct presence allows us to support customers locally, accelerate adoption and help teams turn AI into an operational capability, beyond a promising concept." Neural Concept has also appointed Dr. Eunjoo Lee as Board Advisor. Based in Korea, she brings over two decades of experience in enterprise AI and digital transformation, including leadership roles as former CEO of IBM Korea and Executive Vice President at Samsung, strengthening the company's APAC presence. For manufacturers in the region, the move comes as AI adoption enters a new phase. Rather than layering AI onto legacy systems through disconnected experiments, leading engineering organizations are looking for infrastructure that can support production-scale workflows, governance and measurable business impact. Neural Concept's AI-native architecture is designed for that transition, providing an intelligence layer that fits directly into the way engineering teams already work. "Neural Concept's platform demonstrated promising capabilities that could help accelerate our design workflows and make AI adoption far more practical," said Dongkwon Lee, SVP of Basic Performance Research Center, Hanwha Ocean. The Seoul office opening builds on Neural Concept's global expansion, including the company's growth in the United States and its $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives. As adoption accelerates across Korea, Japan and other major industrial markets, Neural Concept is investing in the local presence and delivery capabilities needed to help manufacturers scale Engineering Intelligence across the enterprise. About Neural Concept Neural Concept provides the intelligence layer for engineering, enabling companies to design and develop complex, high-performance products faster and more efficiently. Its AI-native platform embeds physics-aware intelligence directly into design and simulation workflows, empowering engineering teams to make continuous, AI-augmented decisions at every stage of product development. Founded in 2019, Neural Concept serves leading OEMs and engineering organizations across automotive, aerospace, energy, consumer electronics, semiconductors and defense. Headquartered in Switzerland, the company has a growing global presence including offices in Munich, New York and the Asia-Pacific region, and is backed by global investors, including Goldman Sachs, Forestay Capital and D. E. Shaw Group. Visit https://www.neuralconcept.com Media Contact:Valerie Serinoneuralconcept@5wpr.com
A global vision and platform shaping the finance and accounting profession's future through trust, technology, and human-led transformation KUALA LUMPUR, Malaysia, June 9, 2026 /PRNewswire/ -- The Association of International Certified Professional Accountants (AICPA and CIMA) today launched Rise2040: Shaping the Future of Finance and Accounting, a global initiative designed not simply to anticipate the future of the profession but to actively shape it. Developed through a structured global dialogue spanning more than 25 countries and 6,000 accounting and finance professionals, the Rise2040 initiative manifests itself as a living program of insights which are being combined to deliver a shared vision of how the profession will evolve. "Rise2040 is not about predicting a single future, it's about equipping the profession to actively shape it," said Mark Koziel, CPA, CGMA, CEO of AICPA and CIMA. "We are at a defining moment. As AI reshapes how work gets done, our value will increasingly be defined by human judgment, trust, and the ability to lead in complexity. At the initiative's core sits the Rise2040 AI platform and flagship report; both reinforce a defining insight … the future of the profession will not be determined by what happens to us, by the forces shaping it, but by how we choose to respond." From Reporting the Past to Shaping the Future The Rise2040 vision highlights a profound transformation already underway. As automation reshapes routine work, the profession is rapidly shifting from a historical reporter to an "anticipatory advisor". At the same time, trust remains the profession's enduring core, but one that is increasing in value. In a world saturated with AI and data, human judgment, ethics, and accountability are becoming even more critical differentiators. "What emerged from this global effort is a profession that is not retreating from change but rising to meet it with humans in the lead," said Tom Hood, EVP, Business Engagement & Growth at AICPA and CIMA. The report identifies five interconnected drivers shaping the profession's future: Technology and data infrastructure Value model transformation Talent and workforce dynamics Regulatory and trust architecture Market and societal expectations Together, these forces are transforming how work is performed, how value is created, and how professionals lead. Notably, participants emphasized that technology is not replacing the profession, it is amplifying it, freeing professionals to focus on higher-value activities such as advisory, strategy and decision-making enablement. A Call to Lead … Not React Unlike prior visioning efforts, Rise2040 is designed as an ongoing platform, not a one-time report. It is a continuous system for capturing insights and translating them into action across the global profession. The initiative will continue to evolve through expanded engagement, deeper analysis, and practical tools to help firms, organizations, and professionals access and apply insights in real time. Shaping What Comes Next "Rise2040 ultimately reinforces a shared responsibility," added Koziel. "The future of the profession is not predetermined. It will be shaped by the choices made today." Venkkat Ramanan, FCMA, CGMA, Vice President – Asia Pacific at AICPA and CIMA added: "Across Asia, the transformation of the profession is moving at both scale and pace – powered by a deep talent pipeline, rapid digital adoption and the rising complexity of business. The opportunity is not simply to keep up; it is to lead the shift – moving talent into higher-value, decision-oriented roles where trust, judgment and human leadership are the true differentiators. We are committed to working alongside employers, GCCs, firms, students, government agencies, and the local profession to shape this transition – and Rise2040 is the platform through which we will do it." The insights are clear, the accounting and finance profession is moving "from historian to futurist" – guided by trust, powered by technology, and led by human judgment. About the Association of International Certified Professional Accountants, AICPA, and CIMA The Association of International Certified Professional Accountants (the Association) advances the reputation, employability, and quality of CPAs, CGMA designation holders, and accounting and financial professionals globally. Founded in 2017 by the AICPA and CIMA, it represents 574,000 AICPA and CIMA members, students, and registrants in more than 150 countries and territories, advocating for the public interest and business sustainability on current and emerging issues.
台灣產經新聞網
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
